Beta-Blockers Are NOT Recommended as First-Line Therapy for Primary Hypertension in Adults Without Comorbidities
Beta-blockers should not be used as first-line therapy for uncomplicated hypertension in adults, particularly those aged 60 years or older, due to inferior cardiovascular protection compared to other antihypertensive classes. The evidence consistently demonstrates that beta-blockers are less effective at preventing stroke and provide no mortality benefit over other first-line agents 1, 2, 3.
Preferred First-Line Agents
For adults with primary hypertension without compelling indications, the following agents are recommended as first-line therapy:
- Thiazide/thiazide-like diuretics (longer-acting preferred, such as chlorthalidone)
- ACE inhibitors (in non-Black patients)
- Angiotensin receptor blockers (ARBs)
- Long-acting calcium channel blockers (CCBs)
These four drug classes have demonstrated superior cardiovascular outcomes in high-quality randomized controlled trials 1, 2, 4.
Why Beta-Blockers Fall Short
Inferior Stroke Prevention
The most compelling evidence against beta-blockers as first-line therapy comes from systematic reviews and network meta-analyses showing they are significantly less effective than diuretics for stroke prevention (24-30% lower risk reduction) and cardiovascular events 2, 3, 5. This stroke protection deficit is particularly pronounced in older adults 1, 6, 7.
No Mortality Benefit
Beta-blockers show no difference in all-cause mortality compared to placebo, and actually demonstrate higher mortality compared to calcium channel blockers 5. This stands in stark contrast to other first-line agents that consistently reduce cardiovascular mortality.
Evidence Based on Older Beta-Blockers
Most outcome trials used atenolol, a non-vasodilating beta-blocker now considered inferior 2, 5. Approximately three-quarters of participants in major trials were taking atenolol, which has unfavorable hemodynamic properties including failure to reduce central aortic pressure adequately 5, 8.
Limited Exceptions: Beta-Blockers in Younger Patients
Beta-blockers may be considered as first-line therapy ONLY in patients younger than 60 years with uncomplicated hypertension 1, 9, 10. This age-specific recommendation is based on:
- Different hypertension pathophysiology in younger patients (sympathetic hyperactivity vs. arterial stiffness in elderly)
- Potentially better response to beta-blockade in hyperkinetic circulation states
- Less pronounced stroke risk differential in younger populations
However, even in this younger cohort, beta-blockers remain a Grade B recommendation (lower quality evidence) compared to Grade A recommendations for thiazide diuretics 1, 9.
When Beta-Blockers ARE Appropriate
Beta-blockers should be reserved for patients with compelling indications:
- Post-myocardial infarction
- Heart failure with reduced ejection fraction
- Coronary artery disease
- Atrial fibrillation requiring rate control
- Specific arrhythmias
In these scenarios, beta-blockers provide proven mortality benefit and should be used regardless of age 1, 6.
Common Pitfalls to Avoid
Don't use beta-blockers as first-line in patients ≥60 years - This is a Grade A recommendation against their use 1, 6, 7
Don't combine non-dihydropyridine CCBs with beta-blockers - Risk of excessive bradycardia and heart block 1, 9
Don't assume all beta-blockers are equivalent - Vasodilating beta-blockers (nebivolol, carvedilol) have more favorable hemodynamic profiles than atenolol, though outcome data remain limited 8, 11
Don't prescribe beta-blockers for isolated systolic hypertension in elderly patients - They are specifically not recommended for this indication 7, 12
Practical Treatment Algorithm
For uncomplicated hypertension:
Age <60 years: Consider thiazide diuretic, ACE inhibitor (non-Black), ARB, or long-acting CCB as first-line. Beta-blockers are acceptable but not preferred.
Age ≥60 years: Use thiazide diuretic, ACE inhibitor (non-Black), ARB, or long-acting CCB. Do NOT use beta-blockers as first-line 1, 6.
Stage 2 hypertension (≥140/90 mmHg): Initiate with two-drug combination, preferably single-pill combination of ACE inhibitor/ARB + CCB or ACE inhibitor/ARB + thiazide diuretic 2, 4, 13.
Recent Guideline Controversy
The 2024 ESC guidelines controversially upgraded beta-blockers to equal status with other first-line agents 13, but this decision has been strongly criticized as lacking new supporting evidence and potentially leading to widespread harm due to inferior stroke protection 12. The 2025 ACC/AHA guidelines maintain that beta-blockers are not preferred first-line agents, consistent with the weight of evidence 4.
The consensus from North American guidelines (Hypertension Canada, ACC/AHA) remains clear: beta-blockers should not be first-line therapy for uncomplicated hypertension, especially in patients aged 60 years or older 1, 2, 10, 4.